TheraSphere (yttrium 90 microspheres) / Boston Scientific - LARVOL DELTA

EMERALD-Y90: A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE (clinicaltrials.gov) - P2 | N=58 | Active, not recruiting | Sponsor: AstraZeneca | Trial completion date: Jan 2027 ➔ Jul 2026 | Trial primary completion date: Oct 2026 ➔ Jul 2026

Trial completion date • Trial primary completion date • Hepatocellular Cancer • Oncology • Solid Tumor

PROACTIF: Final Results from the Largest, Prospective HCC Real World Study using Yttrium-90 (Y90) Glass (SIO 2026) - "Real world data with TheraSphere affirmed the safety and efficacy of Y90 in large HCC tumors, including patients with PVT, using tailored dosimetry across all BCLC stages. Median OS was particularly long for patients with subsequent surgery. When deciding HCC management, Y90 should be considered a treatment option, either alone, sequenced, or combined with other treatments, by multidisciplinary tumor boards."

Clinical • Real-world • Real-world evidence • Hepatocellular Cancer • Thrombosis

1st vs. 2nd Week - The Impact of Delivery Timing ofYttriumm-90 Microspheres for Hepatocellular Carcinoma (SIO 2026) - "Materials and A retrospective, single-institution study was performed on patients treated with yttrium-90 glass microspheres for solitary hepatocellular carcinoma from 2024-2025... Timing of y90 dose delivery for solitary HCC does not appear to significantly impact dose delivery to tumor or surrounding normal tissue. Second week delivery resulted in significantly higher sphere concentration in the tumor than in week one. Clinical and radiographic outcomes demonstrate similar efficacy and safety profiles regardless of delivery timing."

Hepatocellular Cancer • Oncology • Solid Tumor

Pre-Procedure MELD 3.0 is a Predictor of Short-Term Mortality and Impaired Liver Function Following Yttrium-90 Radioembolization (SIO 2026) - "Materials and TARE procedures performed using TheraSphere (Boston Scientific Corporation... Elevated pre-procedure MELD 3.0 reflects elevated risk for mortality and impaired synthetic liver function following TARE with various dosing strategies and treatment intents. Scores of 10 and 20 are reasonable thresholds to consider while discussing the elevated risk of impaired liver function and mortality, as 1 in 5 patients exceeding each threshold experienced the respective AE. Future multivariate analysis will determine whether pre-procedure MELD 3.0 modifies risk in patients stratified by non-tumor liver absorbed dose, and whether this effect can be predicted using a Tc-99mmacroaggregated albumin mapping study prior to TARE."

Hepatology

Exhibit Hall & Industry Lunch Symposium: TheraSphereTM Y-90 Glass Microspheres: Preparing for PROACTIF and the Role of Real-World Evidence (SIO 2026) - "Sponsored by Boston Scientific."

Clinical • HEOR • Real-world • Real-world evidence

ReLIVE: Affordable Made-in-India Microspheres for Liver Cancer Therapy (clinicaltrials.gov) - P1 | N=18 | Not yet recruiting | Sponsor: Post Graduate Institute of Medical Education and Research, Chandigarh

New P1 trial • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor

Lunch & Industry-Sponsored Event | Presented by Boston Scientific* TheraSphereTM Y-90 Glass Microspheres: PROACTIF and the Role of Real-World Evidence (HCC-LIVE 2026) - "Supported by Boston Scientific."

Clinical • HEOR • Real-world • Real-world evidence

EMERALD-Y90: A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE (clinicaltrials.gov) - P2 | N=56 | Active, not recruiting | Sponsor: AstraZeneca | Recruiting ➔ Active, not recruiting

Enrollment closed • Hepatocellular Cancer • Oncology • Solid Tumor

INDIGO: TheraSphere Japan Pre-Market Study (clinicaltrials.gov) - P=N/A | N=51 | Recruiting | Sponsor: Boston Scientific Corporation

New trial • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor

FRONTIER: A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: Boston Scientific Corporation | Trial completion date: Jun 2026 ➔ Jan 2027 | Trial primary completion date: Mar 2026 ➔ Jul 2026

First-in-human • Trial completion date • Trial primary completion date • Brain Cancer • Glioblastoma • Neutropenia • Oncology • Solid Tumor

Downstaging HCC: Prolonging Survival with TheraSphereTM Y-90 Therapy (LCS 2026) - "Sponsored by Boston Scientific"

Gastrointestinal Cancer • Hepatocellular Cancer

PROACTIF: Final results from the largest prospective real-world study of 1196 primary liver cancer patients treated with yttrium-90 glass transarterial radioembolization (LCS 2026) - "Method All patients treated with Y90 glass microspheres (TheraSphere™) in 34 French institutions between 2019 and 2024 who agreed to data collection were included...There was meaningful survival, and an acceptable adverse event profile in both indications. Importantly, Y90 followed by surgery resulted in survival outcomes rarely observed in this population of patients typically not eligible for surgery."

Clinical • Real-world • Real-world evidence • Biliary Cancer • Cholangiocarcinoma • Gastrointestinal Cancer • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor

Yttrium-90 Radiation Segmentectomy for Hepatocellular Carcinoma (clinicaltrials.gov) - P=N/A | N=64 | Not yet recruiting | Sponsor: University of California, San Francisco | Trial completion date: May 2028 ➔ Dec 2028 | Initiation date: Nov 2025 ➔ May 2026 | Trial primary completion date: May 2028 ➔ Dec 2028

Trial completion date • Trial initiation date • Trial primary completion date • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor

ArTisaN: TheraSphere Selective Internal Radiation Therapy (SIRT) as Treatment for Neuroendocrine Tumours With Liver Mets (clinicaltrials.gov) - P2 | N=24 | Completed | Sponsor: Imperial College London | Recruiting ➔ Completed

Trial completion • Neuroendocrine Tumor • Oncology • Solid Tumor

PROACTIF: Final results from the largest prospective real-world study of 1196 primary liver cancer patients (PLC) treated with yttrium-90 (Y90) glass transarterial radioembolization (TARE). (ASCO-GI 2026) - P | " All patients treated with Y90 glass microspheres (TheraSphere) between 2019 and 2024 who agreed to data collection were included from 34 French institutions... Results from this large prospective real-world study using contemporary TARE treatment highlight its critical role as an integral component in the continuum of care for patients with PLC. In most cases, patients received personalized treatment, resulting in meaningful survival, and an acceptable adverse event profile. Importantly, TARE followed by surgery resulted in survival outcomes rarely observed in this population of patients typically not eligible for surgery."

Clinical • Real-world • Real-world evidence • Biliary Cancer • Cholangiocarcinoma • Gastrointestinal Cancer • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor

Safety and Feasibility of Yttrium-90 Glass Microsphere Radiation Therapy in Recurrent Glioblastoma: Results from the first 12 patients treated in the FRONTIER trial (SNO 2025) - "Results from this initial cohort suggest IA Y90-microsphere therapy is technically feasible and well-tolerated in rGBM. Further investigation is warranted."

Clinical • Brain Cancer • Glioblastoma • Hepatocellular Cancer • Solid Tumor

Safety and Feasibility of Yttrium-90 Glass Microsphere Radiation Therapy in Recurrent Glioblastoma: Results from the first 12 patients treated in the FRONTIER trial (WFNOS 2025) - "Results from this initial cohort suggest IA Y90-microsphere therapy is technically feasible and well-tolerated in rGBM. Further investigation is warranted."

Clinical • Brain Cancer • Glioblastoma • Hepatocellular Cancer • Oncology • Solid Tumor

EMERALD-Y90: A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE (clinicaltrials.gov) - P2 | N=60 | Recruiting | Sponsor: AstraZeneca | N=100 ➔ 60

Enrollment change • Hepatocellular Cancer • Oncology • Solid Tumor

Comparative Efficacy and Safety of Yttrium-90 Glass vs Resin-Based Microspheres in Hepatocellular Carcinoma Treatment: A Systematic Review and Meta-Analysis (ACG 2025) - "Glass (TheraSphere) and resin (SIR-Spheres) based microspheres are used, but comparative outcomes remain debated... Five studies with 460 patients (252 glass, 208 resin) were analyzed – two retrospective non-randomized trials and three retrospective cohort studies. The population included 376 males (81.7%) with mean or median ages ranging from 60 to 69 years. Baseline characteristics are summarized in Table 1."

Retrospective data • Review • Anorexia • Fatigue • Hepatocellular Cancer • Oncology • Solid Tumor

Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk (clinicaltrials.gov) - P2 | N=84 | Suspended | Sponsor: Northwestern University | Trial primary completion date: Jul 2025 ➔ Jul 2026

Trial primary completion date • Hepatocellular Cancer • Oncology • Solid Tumor

PROACTIF: Final results from the largest, prospective HCC real-world study using Yttrium-90 (Y90) glass microspheres (ESMO 2025) - P | "Background PROACTIF was an all comers, multicenter, post approval study that evaluated the effectiveness and safety of Y90 glass microspheres (TheraSphere™) for the treatment of liver cancers...Overall patients had long OS, particularly for patients with subsequent surgery across all BCLC stages. When deciding HCC management, Y90 should be considered a treatment option by multidisciplinary tumor boards."

Clinical • Real-world • Real-world evidence • Hepatocellular Cancer • Oncology

Safety and Feasibility of Yttrium-90 Glass Microspheres in Recurrent Glioblastoma: Results from the first 12 patients treated in the FRONTIER trial (EANO 2025) - "Results from this initial cohort of the FRONTIER trial suggest IA Y90 glass microsphere therapy is technically feasible and well-tolerated in patients with recurrent GBM. The observed dose-response relationship warrants further investigation of this modality as a potential treatment option."

Clinical • Brain Cancer • Glioblastoma • Hepatocellular Cancer • Oncology • Solid Tumor

Investigation of the Dosimetry Differences Between Pre-Therapy SPECT/CT and Post-Therapy PET/CT Scan in Selective Internal Radiation Therapy (SIRT) (EANM 2025) - "Materials and Methods Twenty patients who received SIRT using 90Y-Theraspheres (Boston Scientific) were selected...However, there are large tumour absorbed dose differences between pre- and post-therapy imaging suggesting opportunity for optimisation of tumour and liver dose. This arises from a variety of factors including a change in activity distribution, PVE, segmentation methods and inter-operator variability."

Elevated Baseline C-Reactive Protein Is Associated with Treatment Failure and Shorter Survival After Radioembolization with Yttrium-90 Glass Microspheres in Hepatocellular Carcinoma: Validation of LI-RADS R-TRA v2024 [WITHDRAWN] (EANM 2025) - No abstract available

Hepatocellular Cancer • Oncology • Solid Tumor • CRP

Is the Planned Dose Achieved in Yttrium-90 Glass Microsphere Radioembolization? An Examination of Factors Influencing Residual Catheter Activity [WITHDRAWN] (EANM 2025) - No abstract available